A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2016-11-25
Target enrollment:
Participant gender:
Summary
Phase II, randomized, double-blind, placebo-controlled, parallel-group clinical trial of
lebrikizumab in participants with COPD and a history of exacerbations who are treated with
inhaled corticosteroid (ICS) and at least one long-acting bronchodilator inhaler medication.
This study will be conducted to assess the safety, efficacy, and patient-reported outcome
(PRO) measures.